Bristol-Myers Squibb Co (NYSE:BMY)
$ 44.94 0.2 (0.45%) Market Cap: 91.10 Bil Enterprise Value: 138.84 Bil PE Ratio: 0 PB Ratio: 5.52 GF Score: 83/100

Bristol-Myers Squibb Co at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 04:30PM GMT
Release Date Price: $50.97 (+1.17%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Okay, welcome to a special afternoon lunch session where -- I'm Geoff Meacham. I'm the senior biopharma analyst here, and Olivia from my team is on stage with me. We're excited to have Bristol. And up on stage with me is Charlie Bancroft, CFO; and John Elicker from the IR team.

Questions & Answers

Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

So maybe let's start with, Charlie, just kind of what your perspective of -- actually, the topic du jour is the Celgene deal. Maybe just kind of give us your perspective kind of you're -- what pushes and pulls you're hearing from investors. And I have a lot -- quite a bit of follow-up.

Charles A. Bancroft
Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO

Okay. Awesome. So good afternoon, everyone. It's nice to be here. Thanks for inviting us, Geoff. So we're very excited about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot